title: Cabergoline treatment in acromegaly: cons.
abstract: Many options are available for the treatment of acromegaly, including surgery, radiotherapy, and medical treatment. Cabergoline (CAB), a dopamine agonist with high affinity for dopamine receptor type 2, has been used both in monotherapy and in conjunction with somatostatin analogs (SSAs). Although it is administered orally and has a relatively lower-cost in comparison with SSAs, few studies have demonstrated its usefulness, there is a lack of randomized-controlled trials and other drugs (SSAs and pegvisomant) with more data in the literature are available; these issues are the main drawbacks of adopting CAB for the treatment of acromegaly.
authors: Department of Internal Medicine and Endocrine Unit, Neuroendocrinology Research Center, Medical School and Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco, 255, sala 9F, Ilha do Fundão, Rio de Janeiro, 21941-913, Brazil.
authors: Leandro
authors: L
authors: Kasuki
authors: Leonardo
authors: L
authors: Vieira Neto
authors: Mônica R
authors: MR
authors: Gadelha
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline; D015282:Octreotide